A California jury awarded Kevin Reikes $34.21 million in total, plaintiff counsel says, and assigned J&J 40 percent of the responsibility and Dr. Scholl’s foot powder 60 percent, Law.com’s The Recorder and the release report. J&J disputes the evidence and says it will appeal.
Johnson & Johnson’s SEC filing puts its talc reserve’s present value at about $9.0 billion; a California jury awarded Kevin Reikes $34.21 million in total, plaintiff counsel’s release says. Jurors assigned J&J 40 percent of the responsibility and Dr. Scholl’s foot powder 60 percent, Law.com’s The Recorder and the release report; Medtruth reports that the Dr. Scholl’s defendant settled before trial, and The Recorder says J&J was the only defendant at trial. Reikes, a Sacramento-area communications executive who testified that he used talcum powder products from the 1970s, was diagnosed with mesothelioma in June 2025, the release says. The verdict came Monday, November 9, in Alameda County Superior Court, where jurors found J&J 40 percent liable for the medical costs and pain and suffering of Kevin Reikes and his wife, Tina Reikes, and awarded no punitive damages, The Recorder reported. “We will immediately appeal this verdict,” J&J said, according to the drug and device safety site Medtruth.
J&J disputed the scientific evidence presented at trial and maintained that its talc products did not contain asbestos or cause cancer, Medtruth reported, and it challenged the evidence that Reikes used Johnson’s Baby Powder. For anyone pricing a talc claim, the $34.21 million is the jury’s total, and Medtruth reported that J&J will not necessarily be required to pay all of it. J&J’s $5.5 billion third-quarter accrual is tied to a proposed ovarian-cancer resolution, while its filing says mesothelioma claims in North America were allocated to Pecos River Talc LLC, an entity assigned talc liabilities in J&J’s corporate restructurings. Those mesothelioma claims are still going to juries.
The California panel is open to everyone: the verdict count, total damages, median and largest verdict. Subscribe free to open every other state on the map, plus one courtroom story every Monday.
The release says Reikes testified that he regularly used talcum powder products, including Johnson’s Baby Powder. It says he began chemotherapy within a month of the June 2025 diagnosis and has since undergone abdominal and chest surgeries.
Plaintiff counsel’s release says the trial lasted over eight weeks and jurors deliberated for two days. The release says jurors found Johnson’s Baby Powder defective, found J&J negligent in failing to warn consumers about asbestos contamination, and found that failure to warn a substantial factor in causing Reikes’s disease.
The split is where the payment question starts. Medtruth reported that California treats economic and noneconomic damages differently when fault is shared and that the earlier settlement may affect the final judgment.
Before the trial, J&J and Pecos River Talc asked the court to throw out several fraud theories without a trial, a request called summary adjudication. A tentative ruling for the September 3 hearing in Alameda County Superior Court, issued by Judge Patrick McKinney and reposted by DecisionDepot, a California legal research site, shows which theories the judge proposed to cut.
Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.
The judge’s tentative ruling would grant the defendants’ request on fraudulent misrepresentation and conspiracy theories. It said the Reikeses had not identified an affirmative misrepresentation on which they relied or specific facts showing a conspiracy. Tina Reikes’s deposition testimony that she had seen J&J advertisements did not, in the judge’s view, identify a specific false statement.
Fraudulent concealment was different in the tentative ruling. The plaintiffs alleged that J&J had received test results concerning asbestos or asbestos-like fibers in its talc or its suppliers’ talc. Tina Reikes testified that advertisements looked familiar to her, that she trusted the brand, and that packaging suggested the baby powder was safe to use on a baby. The judge wrote that, if proven, the evidence could support an inference that J&J owed the Reikeses a duty to disclose a potential danger. The tentative ruling would let that claim proceed. It was a pretrial decision about whether a claim could be heard, not a finding that the alleged concealment occurred.
The jury findings listed in plaintiff counsel’s release concern a defective product and a failure to warn, and J&J has promised to appeal the verdict.
J&J’s quarterly report to the SEC, its fiscal third-quarter Form 10-Q, reported approximately 76,500 plaintiffs in the United States with direct claims against the company and its affiliates over injuries allegedly associated with talc body powders as of September 27. It put the present value of its talc reserve at approximately $9.0 billion. That reserve covers the ovarian settlement agreement, executed settlement agreements, litigation defense, and other costs. P&L translation: a talc reserve with a present value of about $9.0 billion sits against roughly 76,500 U.S. talc plaintiffs, and what the Reikes verdict costs J&J turns on the share a final judgment assigns it.
The same filing says the proposed ovarian agreement does not affect the mesothelioma docket, which remains ongoing, and lists trials scheduled in various state courts throughout 2026 and beyond.
The prior Friday, November 6, a Massachusetts jury returned a separate $1.9 million talc verdict against J&J. Law360 reported that jurors found J&J responsible for a former talc user’s mesothelioma but not the user’s death; The Recorder identified the court as Suffolk County Superior Court.
Analysis: The proposed ovarian deal does not reach the mesothelioma docket, J&J’s filing says, and those claims are going to juries one case at a time: $1.9 million in Massachusetts, then a $34.21 million total in California three days later. What J&J owes remains unsettled after jurors assigned it 40 percent of responsibility, and J&J has promised to appeal. The case to watch is Reikes v. Block Drug Company, No. 25CV157993.
The readiness check has five questions about your reported litigation practices. Use the summary to choose an operating question to explore.
Take the 2-minute readiness check →Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.